Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience

Background: Programmed death 1 (PD-1) inhibitors—tislelizumab, toripalimab, camrelizumab, and sintilimab—are used for advanced urothelial carcinoma (UC) in China. To date, the efficacy and adverse events (AEs) of these PD-1 inhibitors have been poorly reported for advanced UC.Methods: We reviewed 11...

Full description

Bibliographic Details
Main Authors: Fengze Sun, Dawei Wang, Aina Liu, Tianqi Wang, Dongxu Zhang, Huibao Yao, Kai Sun, Zhongbao Zhou, Guoliang Lu, Jitao Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Pharmacology
Subjects:
urothelial carcinoma
programmed death -1/programmed death ligand 1 (PD-1/PD-L1)
adverse events
chemotherapy
efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.837499/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.837499/full

Similar Items